This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wedege, E.
Right arrow Articles by van den Dobbelsteen, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wedege, E.
Right arrow Articles by van den Dobbelsteen, G.

 Previous Article  |  Next Article 

Infection and Immunity, July 2003, p. 3775-3781, Vol. 71, No. 7
0019-9567/03/$08.00+0     DOI: 10.1128/IAI.71.7.3775-3781.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Antibody Specificities and Effect of Meningococcal Carriage in Icelandic Teenagers Receiving the Norwegian Serogroup B Outer Membrane Vesicle Vaccine

Elisabeth Wedege,1* Betsy Kuipers,2 Karin Bolstad,1 Harry van Dijken,2 L. Oddvar Frøholm,1 Clementien Vermont,2 Dominique A. Caugant,1 and Germie van den Dobbelsteen2

Division of Infectious Disease Control, Norwegian Institute of Public Health, N-0403 Oslo, Norway,1 Laboratory of Vaccine Research, The Netherlands Vaccine Institute, 3720 AL Bilthoven, The Netherlands2

Received 30 December 2002/ Returned for modification 30 January 2003/ Accepted 28 March 2003

Antibody specificities of pre- and postvaccination serum samples from 40 (53%) teenagers who received three doses of the Norwegian Neisseria meningitidis serogroup B vaccine (B:15:P1.7,16) during a previous trial in Iceland (Perkins et al., J. Infect. Dis. 177:683-691, 1998) were analyzed with serum bactericidal activity (SBA) and immunoblotting assays with reference and isogenic meningococcal H44/76 vaccine strains. The H44/76 variants demonstrated significant vaccine-induced SBA to P1.7,16 PorA and Opc but not to PorB, Opa5.5, and a heterologous PorA protein. On blots, immunoglobulin G levels to all these proteins increased significantly after vaccination. Measurement of SBA to the two main variable regions (P1.7 and P1.16) on the P1.7,16 PorA with PorA deletion mutants revealed significantly higher activity to the P1.7,- and P1.-,16 mutants compared to the P1.7,16 strain, indicating exposure of new accessible epitopes. Only 12 (30%) serum samples showed distinct decreases with these or the P1.-,- mutant, with most samples containing SBA to the P1.7 and P1.16 combination. In contrast, P1.16-specific antibodies were mainly found on blots. Thirteen of the vaccinees (32.5%) were carriers of meningococci at the time of the third dose, of whom four (30.8%) harbored strains of the ET-5 complex. Carriage of P1.15 strains was generally reflected in ≥4-fold increases in SBA and distinct immunoglobulin G binding to the P1.19,15 PorA on blots. Although vaccination did not elicit bactericidal activity to the serotype 15 PorB, most carriers of serotype 15 strains showed ≥4-fold increases in SBA to this antigen.

* Corresponding author. Mailing address: Division of Infectious Disease Control, Norwegian Institute of Public Health, P.O. Box 4404 Nydalen, N-0403 Oslo, Norway. Phone: (47)22042699. Fax: (47)22042301. E-mail: elisabeth.wedege{at}fhi.no.

Editor: J. T. Barbieri

Infection and Immunity, July 2003, p. 3775-3781, Vol. 71, No. 7
0019-9567/03/$08.00+0     DOI: 10.1128/IAI.71.7.3775-3781.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Wedege, E., Bolstad, K., Aase, A., Herstad, T. K., McCallum, L., Rosenqvist, E., Oster, P., Martin, D. (2007). Functional and Specific Antibody Responses in Adult Volunteers in New Zealand Who Were Given One of Two Different Meningococcal Serogroup B Outer Membrane Vesicle Vaccines. CVI 14: 830-838 [Abstract] [Full Text]  
  • Findlow, J., Taylor, S., Aase, A., Horton, R., Heyderman, R., Southern, J., Andrews, N., Barchha, R., Harrison, E., Lowe, A., Boxer, E., Heaton, C., Balmer, P., Kaczmarski, E., Oster, P., Gorringe, A., Borrow, R., Miller, E. (2006). Comparison and Correlation of Neisseria meningitidis Serogroup B Immunologic Assay Results and Human Antibody Responses following Three Doses of the Norwegian Meningococcal Outer Membrane Vesicle Vaccine MenBvac.. Infect. Immun. 74: 4557-4565 [Abstract] [Full Text]  
  • Toropainen, M., Saarinen, L., Wedege, E., Bolstad, K., Michaelsen, T. E., Aase, A., Kayhty, H. (2005). Protection by Natural Human Immunoglobulin M Antibody to Meningococcal Serogroup B Capsular Polysaccharide in the Infant Rat Protection Assay Is Independent of Complement-Mediated Bacterial Lysis. Infect. Immun. 73: 4694-4703 [Abstract] [Full Text]  
  • Devoy, A. F., Dyet, K. H., Martin, D. R. (2005). Stability of PorA during a Meningococcal Disease Epidemic. J. Clin. Microbiol. 43: 832-837 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»